Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q92552

UPID:
RT27_HUMAN

ALTERNATIVE NAMES:
28S ribosomal protein S27, mitochondrial; Mitochondrial ribosomal protein S27

ALTERNATIVE UPACC:
Q92552; B4DRT2; Q6P1S1

BACKGROUND:
The Small ribosomal subunit protein mS27, identified by its alternative names 28S ribosomal protein S27, mitochondrial, and Mitochondrial ribosomal protein S27, is integral to mitochondrial protein synthesis. It enhances the translation of mitochondrial mRNA for components of the electron transport chain and interacts with 12S mt-rRNA and tRNA(Glu). Its role extends beyond mitochondrial function, contributing to cell proliferation and tumor growth.

THERAPEUTIC SIGNIFICANCE:
The exploration of Small ribosomal subunit protein mS27's function illuminates its potential as a target for therapeutic intervention. Given its critical role in mitochondrial protein synthesis and cell proliferation, strategies aimed at modulating its activity could lead to breakthroughs in treating mitochondrial disorders and cancer.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.